Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 209-213

  Mounier, Nicolas ^a   Gisselbrecht, Christian ^a  

^a Service D'Hé Matologie Adulte   (France)

Author keywords

diffuse large B cell lymphoma; high dose chemotherapy; rituximab; stem cell transplantation

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINDESINE;

ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; ISOTOPE LABELING; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; STEM CELL TRANSPLANTATION;

EID: 79952006855     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328342b8ad     Document Type: Article

References (26)

1. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109:1857-1861. (Pubitemid 46348180)
2. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma: results of a comprehensive meta-analysis. Cancer Treat Rev 2007; 33:338-346. (Pubitemid 46778207)
3. Haioun C, Mounier N, Emile JF, et al. Rituximab versus observation after highdose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 2009; 20:1985-1992.
4. Tarella C, Zanni M, Di Nicola M, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximabsupplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21:1802-1811. (Pubitemid 47086769)
5. Mounier N, Gisselbrecht C, Fitoussi O, et al. Benefit of rituximab combined with ACVBP (R-ACVBP) over ACVBP in 209 poor-risk BDLC NHL patients treated with up-front consolidative autotransplantation: a GELA phase II trial (LNH 2003-3). American Society of Clinical Oncology. 45th Annual Meeting, Abstract 8507.
6. J Clin Oncol 2009; 27:435.
7. Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009; 94:1250-1258.
8. Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre and posttransplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110:1361-1369. (Pubitemid 47435610)
9. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4. cycles of chemotherapy. J Nucl Med 2009; 50:527-533.
10. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 2008; 20:206-219. (Pubitemid 351317410)
11. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dosedense immunochemotherapy determined by interim FDG-PET in advancedstage diffuse large B-cell lymphoma. J Clin Oncol 2010; 28:1896-1903.
12. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50:1-4.
13. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009; 27:2739-2741.
14. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 2008; 143:607-621.
15. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:4184-4190.
16. Sureda A, Canals C, Mounier N, et al. High dose therapy and autologous stem cell transplantation for DLBCL still improves progression-free survival in first relapse in the rituximab era: a study using patients as their own controls. American Society of Hematology 50th Annual Meeting 2008. Abstract 2191.
17. Blood 2008; 112:764.
18. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23:2240-2247. (Pubitemid 46218716)
19. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non- Hodgkin lymphoma. Blood 2004; 103:777-783. (Pubitemid 38129532)
20. Gisselbrecht C, Bethge W, Duarte RF, et al. Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40:1007-1017. (Pubitemid 350147685)
21. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:90-95.
22. Shimoni A, Zwas ST, Oksman Y, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35:534-540. (Pubitemid 46427967)
23. Maloney D. Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant 2008; 42 (Suppl 1): S35-S36.
24. Rezvani AR, Norasetthada L, Gooley T, et al. Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143:395-403.
25. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:426-432.
26. Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16:78-85.